(LYRA) – PRNewswire
-
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study
-
LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting
-
Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients
-
Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022
-
Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting
-
Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer
-
Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022
-
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Lyra Therapeutics to Present at Upcoming Investor Conferences
-
Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
Lyra Therapeutics to Present at Upcoming Investor Conferences
-
Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022
-
Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients
-
Lyra Therapeutics Announces Two Presentations at Upcoming COSM 2022
-
Lyra Therapeutics Announces Closing of $100.5 Million Private Placement
-
Lyra Therapeutics Announces $100.5 Million Private Placement
-
Lyra Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
-
Lyra Therapeutics Appoints Jim Tobin to Board of Directors
-
Lyra Therapeutics Announces First Patient Dosed in Pivotal ENLIGHTEN I Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients
-
Lyra Therapeutics Appoints Harlan W. Waksal, MD, as Executive Chairman
-
Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis Patients
-
Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences
-
Lyra Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-
Lyra Therapeutics to Report Third Quarter 2021 Financial Results on November 9
-
Lyra Therapeutics to Highlight LYR-210 and LYR-220 Clinical Programs at Virtual Event with Leading Clinical CRS Experts
-
Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTERN Manuscript Wins Award at the 67th Annual Meeting of the American Rhinologic Soci
Back to LYRA Stock Lookup